Literature DB >> 1033050

Genetic study of amobarbital elimination based on its kinetics in twins.

L Endrenyi, T Inaba, W Kalow.   

Abstract

Following the intravenous administration of 125 mg amobarbital sodium in 7 pairs of dizygotic and 7 pairs of monozygotic twins, the time-course of plasma concentrations was observed. The number of detectable compartments varied from subject to subject but was consistently 1 or 2 or 3 within a given individual. The terminal slope of the semilogarithmic concentration-time plot (corresponding to biologic half-life of 22.8 hr) did not represent the elimination rate constant even in persons with apparently single-compartmental characteristics. The redistribution of amobarbital was rapid in comparison with its elimination. The rate of the latter (characterized by kel = 0.051 hr-1, plasma clearance = 37.7 ml/min) could be closely identified with the rate of metabolism. The twin data showed that genetic control was exerted on kinetic parameters characterizing the rate of amobarbital elimination and, therfore, the rate of its metabolism. Correlation analysis suggested that this control was independent of size factors, which were themselves substantially heritable. The genetic analysis of twin data included, in addition to intracelass correlations and Holzinger's H factors, newly developed lower (and upper) bounds of the broad-sense heritability. In pharmacogenetic studies, assessment of model-independent kinetic parameters, such as plasma clearance with or without adjustment for body weight, is recommended.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1033050     DOI: 10.1002/cpt1976206701

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Clinical pharmacokinetics of hypnotics.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

2.  Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).

Authors:  Vural Ozdemir; Laszlo Endrenyi; Sükrü Aynacıoğlu; Nicola Luigi Bragazzi; Collet Dandara; Edward S Dove; Lynnette R Ferguson; Christy Jo Geraci; Ernst Hafen; Belgin Eroğlu Kesim; Eugene Kolker; Edmund J D Lee; Adrian Llerena; Muradiye Nacak; Kazutaka Shimoda; Toshiyuki Someya; Sanjeeva Srivastava; Brian Tomlinson; Effy Vayena; Louise Warnich; Umit Yaşar
Journal:  OMICS       Date:  2014-03-20

Review 3.  Individual differences in the disposition of drugs metabolised in the body.

Authors:  G Alvan
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 4.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 5.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

6.  [Perdormal kinetics].

Authors:  G L Dadisch
Journal:  Z Rechtsmed       Date:  1983

7.  Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.

Authors:  M B Penno; E S Vesell
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

8.  Enzyme induction following a single dose of amobarbital in dogs.

Authors:  P A Reilly; T Inaba; D Kadar; L Endrenyi
Journal:  J Pharmacokinet Biopharm       Date:  1978-08

9.  Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins.

Authors:  M B Penno; B H Dvorchik; E S Vesell
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

10.  BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSIS.

Authors:  Joshua B Ewen; William Z Potter; John A Sweeney
Journal:  Biomark Neuropsychiatry       Date:  2021-01-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.